Setting & Population
- Vascular access
- outcome measures
- standardized outcomes
- outcome reporting
- evidence-based practice
- end-stage renal disease (ESRD)
- arteriovenous fistula (AVG)
- central venous catheter (CVC)
- arteriovenous graft (AVG)
- systematic review
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Trends in incident hemodialysis access and mortality.JAMA Surg. 2015; 150: 441-448
- Complications of the arteriovenous fistula: a systematic review.J Am Soc Nephrol. 2017; 28: 1839-1850
- Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis.Am J Kidney Dis. 2014; 63: 464-478
- Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis.J Am Soc Nephrol. 2005; 16: 201-209
- Associations between hemodialysis access type and clinical outcomes: a systematic review.J Am Soc Nephrol. 2013; 24: 465-473
- The Achilles' heel of the hemodialysis patient.Arch Intern Med. 1978; 138: 1063-1064
- “You know your own fistula, it becomes a part of you”-patient perspectives on vascular access: a semistructured interview study.Hemodial Int. 2015; 20: 5-14
- The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians.Am J Nephrol. 1998; 18: 379-383
- Setting research priorities for patients on or nearing dialysis.Clin J Am Soc Nephrol. 2014; 9: 1813-1821
- Establishing core outcome domains in hemodialysis: report of the Standardised Outcomes in Nephrology – Hemodialysis (SONG-HD) consensus workshops.Am J Kidney Dis. 2017; 69: 97-107
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.Cochrane Database Syst Rev. 2015; 7: CD002786
- Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis.Am J Kidney Dis. 2013; 61: 112-122
- Vascular access in haemodialysis: strengthening the Achilles' heel.Nat Rev Nephrol. 2013; 9: 348-357
- Hemodialysis patients' satisfaction and perspectives on complications associated with vascular access related interventions: are we listening?.J Vasc Access. 2016; 17: 313-319
- Core Outcome Set-STAndards for Reporting: the COS-STAR statement.PLoS Med. 2016; 13: e1002148
- Systematic review of the empirical evidence of study publication bias and outcome reporting bias.PLoS One. 2008; 3: e3081
- Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review.PLoS One. 2013; 8: e66844
- How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” - a practical guideline.Trials. 2016; 17: 449
- Better reporting and greater homogeneity in outcome measures are seen in randomized trial protocols when guidelines exist.J Clin Epidemiol. 2013; 66: 838-846
- Increasing value and reducing waste in research design, conduct, and analysis.Lancet. 2014; 383: 166-175
- Biomedical research: increasing value, reducing waste.Lancet. 2014; 383: 101-104
- Standardized definitions for hemodialysis vascular access.Semin Dial. 2011; 24: 515-524
- Recommended standards for reports dealing with arteriovenous hemodialysis accesses.J Vasc Surg. 2002; 35: 603-610
- Society of Interventional Radiology Technology Assessment Committee. Reporting standards for percutaneous interventions in dialysis access.J Vasc Interv Radiol. 2003; 14: S433-S442
- Clinical practice guidelines for vascular access.Am J Kidney Dis. 2006; 48: S248-S273
- The ClinicalTrials.gov results database–update and key issues.N Engl J Med. 2011; 364: 852-860
- Patient reported outcome measures could help transform healthcare.BMJ. 2013; 346: f167
- Surrogate end points in clinical trials: are we being misled?.Ann Intern Med. 1996; 125: 605-613
NKF-KDOQI Guidelines. Clinical practice guidelines and clinical practice recommendations 2006. https://www.kidney.org/professionals/guidelines/guidelines_commentaries. Accessed January 22, 2017.
- Preventing infections associated with indwelling intravascular access devices.Can Commun Dis Rep. 1997; 23 (i-iii, 1-32, i-iv, 31-16)
- Guidelines for the management of intravascular catheter-related infections.Clin Infect Dis. 2001; 32: 1249-1272
- Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention.MMWR Recomm Rep. 2002; 51: 1-29
- Hemodialysis arteriovenous fistula maturity: US evaluation.Radiology. 2002; 225: 59-64
- Society of Interventional Radiology Technology Assessment C. Reporting standards for central venous access.J Vasc Interv Radiol. 2003; 14: S443-S452
- The OMERACT Handbook.OMERACT, Ottowa, ON, Canada2014
- Standardised Outcomes in Nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis.Trials. 2015; 16: 364
- Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey.Am J Kidney Dis. 2017; 70: 464-475
Standardised Outcomes in Nephrology - Haemodialysis (SONG-HD) Expert Working Groups. http://songinitiative.org/who-we-are/expert-working-groups/. Accessed August 7, 2017.
- Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.JAMA. 2008; 299: 2164-2171
- The Vascular Access Questionnaire: assessing patient-reported views of vascular access.J Vasc Access. 2008; 9: 122-128
Allon M, Brouwer-Maier DJ, Abreo K, et al. Recommended clinical trial end points for dialysis catheters [published online ahead of print July 20, 2017]. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.12011116.
Beathard GA, Lok CE, Glickman MH, et al. Definitions and end points for interventional studies for arteriovenous dialysis access [published online ahead of print July 20, 2017]. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.11531116
Hurst FP, Lee RE, Thompson AM, Pullin BD, Silverstein DM. FDA regulatory perspectives for studies on hemodialysis vascular access [published online ahead of print July 24, 2017]. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.02900317
Standardised Outcomes in Nephrology - Haemodialysis (SONG-HD) Initiative. 2016. http://songinitiative.org/about-us/song-hd/. Accessed August 7, 2017.
- Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis.J Am Soc Nephrol. 2011; 22: 1939-1945
Complete author and article information provided before references.
Authors’ Full Names and Academic Degrees: Andrea K. Viecelli, MD, Emma O’Lone, MBChB, Benedicte Sautenet, PhD, Jonathan C. Craig, PhD, Allison Tong, PhD, Eric Chemla, MD, Lai-Seong Hooi, MD, Timmy Lee, PhD, Charmaine Lok, MSc, Kevan R. Polkinghorne, PhD, Robert R. Quinn, MD, PhD, Tushar Vachharajani, MD, Raymond Vanholder, PhD, Li Zuo, PhD, Ashley B. Irish, MD, Trevor A. Mori, PhD, Elaine M. Pascoe, MBiostat, David W. Johnson, PhD, and Carmel M. Hawley, MMed Sci.
Authors’ Contributions: Research ideas and study design: AV, EO, BS, AT, JC, CH; data acquisition: AV, EO; data analysis and interpretation: AV, EO, BS, AT, CH, JC; supervision or mentorship: AT, JC, EC, LH, TL, CL, KP, RQ, TV, RV, LZ, AI, TM, EP, DJ, CH. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Support: This project is supported by a National Health and Medical Research Council (NHMRC) program grant ( 1092597 ) and project grant (1098815). Dr Viecelli receives grant support from the NHMRC Medical Postgraduate Scholarship ( 1114539 ) and the Royal Australasian College of Physicians (Jacquot NHMRC Award for Excellence). Dr O’Lone receives support from the NHMRC Medical Postgraduate Scholarship ( 1114189 ), Drs Tong and Mori are supported by NHMRC Research Fellowships ( 1106716 and 1042255 ), and Dr Johnson is supported by an NHMRC Practitioner Fellowship ( 1117534 ). The funders had no role in the design and conduct of the study; collection; management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Financial Disclosure: Drs Irish and Polkinghorne have received travel sponsorship from Amgen Australian Pty Ltd. Dr Irish has received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care; Dr Vanholder received travel support, speaker’s honoraria, and consultancy fees from Fresenius Medical Care, Nipro, Nikisso, Bayer and Astra-Zeneca. The remaining authors declare that they have no other relevant financial interests.